Transcenta Holding Limited
HKSE: 6628.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Xueming Qian
- Employees
- 184
- Headquarters
- Suzhou, China
- IPO year
- 2021
- Market cap
- HK$905.5M
- Website
- https://www.transcenta.com
Loading 6628…
Loading profile data…Frequently asked questions about 6628
What does Transcenta Holding Limited (6628.HK) do?
Transcenta Holding Limited, a clinical stage biopharmaceutical company, engages in the discovery, research, development, manufacture, and commercialization of various drugs in the People's Republic of China and the United States. The company develops MSB2311, a humanized PD-L1 monoclonal antibody (mAb) candidate for TMB-H solid tumors; TST001, a...
Where does 6628.HK trade?
Transcenta Holding Limited (6628.HK) trades on the Hong Kong Stock Exchange.
What sector is 6628.HK in?
Transcenta Holding Limited (6628.HK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Transcenta Holding Limited?
Xueming Qian is the chief executive officer of Transcenta Holding Limited (6628.HK).
Where is Transcenta Holding Limited headquartered?
Transcenta Holding Limited is headquartered in China.
Does 6628.HK pay a dividend?
Transcenta Holding Limited (6628.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 6628.HK go public?
Transcenta Holding Limited (6628.HK) completed its initial public offering in 2021.